Penserra Capital Management’s Pacific Biosciences PACB Stock Holding History

Penserra Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-310	Closed	-$2K	–	1195
2022 Q4	$2K	Buy	+310	New	+$2.67K	﹤0.01%	1058
2021 Q4	–	Sell	-4,560	Closed	-$116K	–	1495
2021 Q3	$116K	Buy	4,560 +45	+1%	+$1.33K	﹤0.01%	738
2021 Q2	$157K	Buy	4,515 +150	+3%	+$4.36K	﹤0.01%	688
2021 Q1	$145K	Buy	4,365 +70	+2%	+$2.45K	﹤0.01%	639
2020 Q4	$111K	Buy	4,295 +2,785	+184%	+$47.3K	﹤0.01%	594
2020 Q3	$14K	Buy	+1,510	New	+$8.69K	﹤0.01%	782

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Penserra Capital Management's PACB Position: Q1 2023 in Review

Penserra Capital Management sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 310 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in PACB in Q3 2020 and held it in 6 quarters. The position peaked at $157K in Q2 2021. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

Penserra Capital Management reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
Penserra Capital Management sold 310 Pacific Biosciences shares in Q1 2023, an estimated $2K.
Penserra Capital Management first reported a position in Pacific Biosciences in Q3 2020 and held it in 6 quarters.
Penserra Capital Management's Pacific Biosciences position peaked at $157K in Q2 2021.
259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Penserra Capital Management's 13F filing for Q1 2023, filed 24 Apr 2023.